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BACKGROUND: Chemotherapy-resistant cancer stem cells (CSC) may lead to tumor recurrence in glioblastoma (GBM).
The poor prognosis of this disease emphasizes the critical need for developing a treatment stratification system to improve
outcomes through personalized medicine. METHODS: We present a case series of 12 GBM and 2 progressive anaplastic
glioma cases from a single Institution prospectively treated utilizing a CSC chemotherapeutics assay (ChemoID) guided
report. All patients were eligible to receive a stereotactic biopsy and thus undergo ChemoID testing. We selected one of
the most effective treatments based on the ChemoID assay report from a panel of FDA approved chemotherapy as mono-
therapy or their combinations for our patients. Patientswere evaluated byMRI scans and responsewas assessed according
to RANO 1.1 criteria. RESULTS:Of the 14 cases reviewed, themedian age of our patient cohort was 49 years (21–63).We
observed 6 complete responses (CR) 43%, 6 partial responses (PR) 43%, and 2 progressive diseases (PD) 14%. Patients
treated with ChemoID assay-directed therapy, in combination with other modality of treatment (RT, LITT), had a longer
median overall survival (OS) of 13.3 months (5.4-NA), compared to the historical median OS of 9.0 months (8.0–10.8
months) previously reported. Notably, patients with recurrent GBM or progressive high-grade glioma treated with
assay-guided therapy had a 57% probability to survive at 12 months, compared to the 27% historical probability of sur-
vival observed in previous studies. CONCLUSIONS: The results presented here suggest that the ChemoID Assay has the
potential to stratify individualized chemotherapy choices to improve recurrent and progressive high-grade glioma patient
survival.
Importance of the Study: Glioblastoma (GBM) and progressive anaplastic glioma are the most aggressive brain tumor in
adults and their prognosis is very poor even if treated with the standard of care chemoradiation Stupp's protocol. Recent
knowledge pointed out that current treatments often fail to successfully target cancer stem cells (CSCs) that are responsible
for therapy resistance and recurrence of these malignant tumors. ChemoID is the first and only CLIA (clinical laboratory
improvements amendment) -certified and CAP (College of American Pathologists) -accredited chemotherapeutic assay
currently available in oncology clinics that examines patient's derived CSCs susceptibility to conventional FDA (Food
and Drugs Administration) -approved drugs. In this study we observed that although the majority of our patients
(71.5%) presented with unfavorable prognostic predictors (wild type IDH-1/2 and unmethylated MGMT promoter), pa-
tients treated with ChemoID assay-directed therapy had an overall response rate of 86% and increased median OS of
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13.3 months compared to the historical median OS of 9.1 months (8.1–10.1 months) previously reported [1] suggesting
that the ChemoID assay may be beneficial in personalizing treatment strategies.
Introduction
Glioblastoma (GBM) and progressive anaplastic glioma are the most ag-
gressivebrain tumor inadults, exhibitingaverypoorprognosiswithamedian
timeto recurrence forGBMofapproximately7months, andamediansurvival
of 15–18 months even if treated with standard of care consisting of surgical
resection/biopsy, and concurrent radiation with Temozolomide followed by
adjuvant Temozolomide (TMZ) [2]. Despite this treatment, recurrence is al-
most inevitable, [3] and the prognosis of recurrent GBM remains poor with
a median PFS of 5.5 months, and a median OS of 8–9 months [4]. Unfortu-
nately, no universally held standard of care is available for recurrent GBM
and progressive anaplastic glioma. Treatment options depend on specific as-
pects of its presentation, including secondary cytoreductive surgery when
possible, focused re-irradiation [5], andnumerous second-line chemotherapy
treatment options [6]. While most patients eventually succumb to the pro-
gressionof recurrentdisease, second-line chemotherapy treatmentshavepro-
vided variable remission and symptom-free survival in a percentage of
patients [6].As such, the selectionof effective chemotherapy is extremely im-
portant for these patients. Additionally, with emerging value-based payment
models where outcomes-based contracts link to payment for indications of
specific cancer drug prices, there are further concerns about the accessibility
andaffordability for treatmentof recurrentGBMpatients; therefore, there is a
need foreffective treatments that limitoverall costwhilealso increasing treat-
ment value for these patients.
Herein we describe our experience in using ChemoID, a clinical lab-
oratory improvements amendment (CLIA)-certified and College of
American Pathologists (CAP)-accredited clinical diagnostic test that is
performed in a clinical pathology laboratory, which identifies chemo-
therapeutic agent(s) that kill both the cancer stem cells (CSCs) and the




Fourteen patients (11males and 3 females), 18 years and older, that were
clinically diagnosedwith recurrent GBM (12 patients) or progressive anaplas-
tic glioma (2 patients), received a concurrent stereotactic biopsy for histologi-
cal diagnosis and for prospectiveChemoIDchemotherapeutic testing between
October 2016 andOctober 2017. This studywas approved by the Institutional
ReviewBoard (IRB)and informedconsentwasobtained.Patientswere treated
withChemoID-guided chemotherapyaccording to their overall functional sta-
tus and ability to tolerate the recommended treatment. Radiological data was
collected before surgery, immediately post-surgery and following chemo/ra-
diation therapy with an MRI follow-up every 2 months. Supportive care was
alsoallowedat thediscretionof the treatingphysician.Disease statuswasmea-
sured by radiologic examination (MR scan as the primary imaging method),
physical examination, and measurements using the Response Assessment in
Neuro-Oncology (RANO1.1)criteria[7],which takes intoaccountparameters
and evaluations to identify pseudo-progression as well as pseudo-response.
The RANO criteria, similarly to other systems, divide response into 4 types
of response based on imaging (MRI) and clinical features [8,9]: complete re-
sponse, partial response, stable disease, and progression.
ChemoID Assay
Multiple fresh GBM tissue samples for ChemoID functional testing were
collected in the operating room from each patient at the time of the stereotac-
tic biopsy procedure. Details regarding cell culture conditions, the CSCs
enrichment procedure and the assay have been previously described
[10–12]. The bulk of tumor cells and CSCs were counted using trypan blue
exclusion to determine cellular viability and cell number prior to
chemosensitivity testing. Cells were also incubatedwithflorescent antibodies
for phenotypic characterization by flow cytometry and also this procedure
has been previously described [10,11]. Percent of cell survival was assessed
using anMTT assay on 1×10∧3 cells plated in 5 replicas into 96-well plates.
An equal number of the bulk of tumor cells and CSCs were seeded in 96-well
dishes and incubated at 37 °C for 24-hours. Three concentrations of each che-
motherapy treatment were prepared by serial dilution. Each concentration
was added to five replicate wells on the microtiter plate. Additionally, three
replicateswells (control 1=no treatment) and three replicates wells (control
2= equal amount of solvent) were associated with each treatment. The cells
were challenged for a 1-hour pulse with the panel of anticancer drugs
(Table 1). MTT assay was performed 24-hours following chemotherapy treat-
ment to assess cell survival as previously described [10–12].
Inhibition of bulk of tumor cells and CSCs survival was measured for
each concentration (average counts in five replicates± SE) of a given treat-
ment (15–18 per patient). Survival of tumor cells at each concentrationwas
calculated as compared to control-2 and overall percent of the bulk of
tumor cells and CSCs killed were calculated for each treatment as the pri-
mary measures of potential therapy efficacy.
Statistical Analysis
Descriptive statistics were constructed as medians with ranges for con-
tinuous variables and counts and percentages for categorical variables.
Table 1
List of single chemotherapeutic agents and combinations tested on the GBM and













7 Procarbazine 60 mg/m2
8 Vincristine 1.4 mg/m2















4 Temozolomide 50 mg/m2
Etoposide 50 mg/m2
5 Temozolomide 50 mg/m2
Imatinib 200 mg
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Due to the small sample size, no survival models were constructed. A graph
displaying censoring/death times for each participantwith annotationswas
constructed along with a Kaplan–Meier plot showing survival probabilities.




Fresh tissue samples were collected for drug sensitivity testing from 12
GBM and 2 progressive anaplastic glioma patients, with a median age of 49
years (range 21–61), 79% of which were male, all eligible for stereotactic
biopsy. Patients were treated with chemotherapies predicted to be most ef-
ficacious by the ChemoID chemotherapeutics assay taking into consider-
ation the patient's tolerability of that particular treatment based on their
health status.
IDH-1 mutation and methylation status of the promoter region of the
O6-Methyl-guanyl-methyl-transferase (MGMT) gene were studied for our
entire patient cohort. About 29% of our patients had methylation of the
MGMT gene promoter, and 86% a wild-type IDH-1/2 status from their pa-
thology report (Table 2).
Table 3 reports the clinical characteristics we have analyzed in our pa-
tient cohort. In particular, 10 patients (72%) presented with IDH-1/2
wild-type and unmethylated MGMT promoter, 2 patients (14%) with
IDH-1/2 wild-type and methylated MGMT promoter, 1 patient (7%) with
IDH-1 mutated and unmethylated MGMT promoter, and 1 patient (7%)
with IDH-1/2 mutated and a methylated MGMT promoter, indicating that
the vast majority of the patients in our cohort had negative prognostic pre-
dictors for their disease (i.e. presence of wild-type IDH-1/2 protein and
unmethylated MGMT gene promoter) [13–16]. The median KPS status of
our patients was 70 (KPS range 60–90). 57% of our patients were re-
irradiated following ChemoID guided therapy. Only one patient in our co-
hort underwent surgical resection as part of the treatment for their recur-
rent GBM, and another one was operated on as a treatment for an infection.
Patients were prospectively monitored by response assessment in
neuro-oncology (RANO 1.1) for tumor response, time to progression,
progression-free survival (PFS), and overall survival (OS). Tables 2 and 3
describe the characteristics of our patient series and their response to ther-
apy observed as per RANO 1.1. We observed 6 complete responses (CR)
43% (6 out of 14 patients), 6 partial response (PR) 43% (6 out of 14 pa-
tients), and 2 progressive diseases (PD) 14% (2 out of 14 patients). How-
ever, the two PD (patients #2 and 4, Figure 1) were observed because
patients could not be treated with ChemoID recommended therapy for
their health status.
All patients had follow-up MRI every 2 months, and the median follow-
up from pre-ChemoID tumor biopsy was 11.4 months (range 4.0–29.4
months). At the end of our follow-up, 7 patients (50%) were still alive.
Figure 1 shows survival times of the recurrent GBM patients prospectively
treated using the ChemoID test results and chemotherapies predicted by
the CLIA-certified and CAP-accredited CSC drug assay.
We observed that the median OS of patients treated with ChemoID
assay-directed therapy was 13.3 months (5.4-NA) compared to the histori-
cal median OS of 9.1 months (8.1–10.1 months) previously reported
Table 2
Patient characteristics
Median age 49 / (21–63)
Female 3 (21%)
Male 11 (79%)
IDH-1/2 wild-type 12/14 (86%)
Unmethylated MGMT promoter 10/14 (71%)
Response
Complete response (CR) 6 (43%)
Partial response (PR) 6 (43%)
Stable disease (SD) 0 (0%)
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(Figure 2) [1]. Notably, our recurrent and progressive high-grade glioma
patient cohort treatedwith ChemoID assay-guided therapy had a 57%prob-
ability to survive at 12 months, compared to the 27% historical probability
of survival at 12months observed in previous studies [17]. Of the surviving
patients, all have exceeded the expected survivals of previously reported
studies [1,4,17]. One-year overall survival was 57% (95% CI: 28% -
78%), based upon Kaplan–Meier estimates.
Figure 3 shows the MRI image of a wild type IDH-1, unmethylated
MGMT, non-operable left midbrain/thalamus GBM patient (Figure 3A),
the ChemoID drug response assay results (Figure 3B), and the subsequent
MRI images (Figure 3, C–H) following treatment with ChemoID-guided
therapy and re-irradiation. This patient received a stereotactic biopsy for
an inoperable left brainstemmass to confirm the presence of a grade IV glio-
blastoma in December of 2016. A concomitant fresh biopsy was sent to the
ChemoID lab for testing. The patient was treated with a full course of irra-
diation to 60 Gy and Temozolomide (TMZ) as per standard of care; how-
ever, the tumor showed radiologic progression in April 2017 (Figure 3C).
At this point, after multidisciplinary discussion, treatment was switched
to BCNU, which had demonstrated bulk tumor effectiveness (88.6% cell
kill) as well as CSC (82.6% cell kill) by the ChemoID assay. MRI images
in November of 2017 following the completion of treatment with 6 cycles
of BCNU (150 mg/m2 every 6 weeks) showed a dramatic reduction of the
tumor burden (Figure 3D). Patient requested maintenance therapy and
was then reirradiated and started on Imatinib (400 mg daily), which also
demonstrated effectiveness on the bulk of tumor (96.3% cell kill) and on
CSC (45.9% cell kill) by the ChemoID assay. MRI images following treat-
ment with Imatinib (February–November 2018) showed an even greater re-
duction of the tumor burden for 24 months with no new lesions (Figure 3,
E–H).
Discussion
Medical management of recurrent GBM and progressive anaplastic gli-
oma is typically a multimodality treatment plan consisting of maximal
safe surgical resection (when possible), followed by radiotherapy with con-
comitant and adjuvant Temozolomide and/or other secondary chemother-
apies [4,18,19] which continually increases treatment morbidity leading to
further cost with diminishing returns on the outcome. Moreover, despite
aggressive therapy and emerging chemotherapeutic treatment options, be-
cause current therapies are not curative and improving overall survivability
has proven to be problematic, the management of these patients remains
difficult.
TMZ is a key component of standard therapy for both newly diagnosed
and recurrent GBM patients; however, the major challenge with recurrent
GBM treatment is the numerous clinically-acceptable and oftentimes equiv-
alent treatment options identified in treatment guidelines [20] . Currently,
there is insufficient evidence to indicate a superior agent or treatment strat-
egy for GBM patients as a whole as well as for the individual patient.
The presence of CSCs appears to be responsible, at least in part, for resis-
tance to standard treatments, the variable responses seen to treatment, and
thus has important implications for the development of a diagnostic assay
to guide personalized treatment regimens [21]. The current study evalu-
ated the clinical advantage of using the ChemoID chemotherapeutics
assay tomeasure CSC response against a panel of FDA approved chemother-
apies to treat recurrent GBM. Patients were treated with chemotherapies
(Table 1) chosen from those drugs showing the highest cell kill as deter-
mined by the CSCs and bulk of tumor chemotherapeutic test response,
and by taking into consideration the patient's tolerability of the treatment.
This study is the first example demonstrating that ChemoID, a CSC che-
motherapeutics assay, can prospectively identify and stratifymore effective
chemotherapy agents versus other possible choices on an individual patient
level in poor prognosis recurrent GBMand progressive anaplastic glioma. In
particular, although 10/14 of our patient cohort (71.5%) presented with
unfavorable prognostic predictors (IDH-1/2 wild type and unmethylated
MGMT promoter) [13–15], we observed that patients treated with
ChemoID assay-directed therapy had an overall response rate of 86%. Nota-
bly, PD was observed in those patients that could not be treated with assay
recommended therapy due to their health status and co-morbidities.
Interestingly, systematic reviews and meta-analysis of re-resection and
re-irradiation for recurrent GBM showed that both practices were associ-
ated with better overall survival and post-progression survival, providing
encouraging disease control and survival rates [22,23]. 57% of the GBMpa-
tients in our cohort, received irradiation following ChemoID guided ther-
apy, but only two recurrent patients underwent surgical resection as part
of their treatment, with one of the two patients that were operated to
treat an infection and not the neoplastic lesion.
It is known that recurrent GBM is associated with a median overall sur-
vival of less than a year and the majority of patients have profound tumor-
related symptoms [24,25]. Interventions such as re-resection, systemic
therapy and/or re-irradiation may benefit selected patients, but unfortu-
nately, all are given with a palliative intent [25]. As such, treatment
Figure 1. Diagram illustrating patient's characteristics, their survival times in months, and their response to treatment according to RANO 1.1 criteria. Abscissae axis shows
survival time in months, ordinate axis shows patient number. Dashed lines indicate deaths, while solid lines indicate right censoring. Treatment response according to RANO
1.1 criteria is indicated by Complete Response (CR), Partial Response (PR) and Progressive Disease (PD).
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decisions must be individualized. Clinicians are tasked with selecting the
most appropriate treatment, balancing the benefits of treatment with the
risk of treatment-related toxicity and its impact on the quality of life
[26,27]. The performance status of the patient, extent of recurrence (focal
versus diffuse) and location of recurrence are important considerations in
such instances [26,27].
Notably, our cohort of GBM and progressive high-grade glioma patients
treated with assay-guided therapy had a 57% probability to survive at 12
months, compared to the 27% historical probability of survival at 12
months observed in previous studies [1,4,17], demonstrating the impor-
tance of determining CSCs response to chemotherapy to prolong patients'
survival. The data further supports the belief that long-term tumor response
in GBM, is in fact, more dependent on the intrinsic sensitivity or resistance
of the CSCs to conventional chemotherapies. This concept is especially
valuable and important with emerging value-based healthcare models
where outcomes-based contracts linked to payment for an indication of spe-
cific anticancer-drug prices raise concerns about the accessibility and af-
fordability for treatment of recurrent GBM patients. The power of
precision medicine lies in its ability to guide health care decisions toward
the most effective treatment for a given patient, and thus, improve care
quality while reducing the need for unnecessary diagnostic testing and
therapies.
ChemoID is a functional precision medicine test that uses patient's live
bulk of tumor cells and cancer stem cells (CSCs) isolated by tumor biopsies
to indicate and to stratify which chemotherapy agent (or “combinations”) is
most effective [12]. Targeting of CSCs alongside the bulk of other cancer
cells is a new paradigm in personalized anticancer treatment. This strategy
and technological advancement constitute an important advantage of
ChemoID approach over other diagnostic methods for personalized
medicine.
We are currently conducting a multi-institutional phase-III clinical trial
(NCT03632135) to determine the clinical validity of the ChemoID assay as
a predictor of clinical response in recurrent GBM. The study has been de-
signed as a parallel-group, controlled clinical trial that randomizes partici-
pants to either standard of care chemotherapy chosen by the physician or
ChemoID-guided therapy. In the NCT03632135 trial, response to therapy
will be measured by MRI imaging using RANO 1.1 criteria to assess overall
survival (OS), OS at 6, 9, and 12 months, median progression-free survival
(PFS), PFS at 4, 6, 9, and 12 months, objective tumor response, time to re-
currence, and quality of life.
ChemoID is the first and only chemotherapeutics assay currently avail-
able in oncology clinics that examines CSCs susceptibility to conventional
FDA approved drugs from solid tumors. Results from the current study indi-
cate that the ChemoID assay may be a very useful tool for optimizing treat-
ment selection when first-line therapy fails, and when there are multiple
clinically acceptable and equivalent treatments available. The ChemoID
assay takes 2 weeks to be completed from the date of receiving a live bi-
opsy, which corresponds to the average time patients spend recovering
from surgery prior to continuing further therapy. Therefore, the ChemoID
assay is suitable for timely, individualized chemotherapy for cancer pa-
tients who received surgery. Furthermore, our results suggest that this indi-
vidualized functional chemotherapeutic assay may indeed surpass the
results achieved by empiric population-based treatment by providing
more treatment options with improved outcomes for many more patients.
This compelling data suggests that the ChemoID CSC assay may be benefi-
cial in personalizing treatment strategies to increase survival time for recur-
rent GBM patients and to provide quality metrics for healthcare payers and
providers to support access to care.
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Figure 2. Kaplan-Meier plot of overall survival probability. Overall survival (OS) for recurrent GBM patients treated with ChemoID-guided responsive drugs. Patients
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Figure 3.MRI Images and comparative analysis of ChemoID test results on Bulk of Tumor and Cancer Stem Cells of a patient affected by left midbrain/thalamus, WHO grade
4, IDHwild-type,MGMTunmethylated gene, not operable, recurrent GBM.A) Preoperative (stereotactic biopsy)MRI shows an intra-axial enhancingmass centered in the left
midbrain/thalamus measuring 2.51× 1.49 cm (12/22/2016). B) Comparative ChemoID analysis on Bulk of Tumor and Cancer Stem Cells obtained from fresh stereotactic
biopsy. C) Control MRI (04/06/2017) following standard of care treatment with Temodar chemotherapy (75 mg/m2 daily) and radiation therapy (with radiation boost – 7
fractions) shows increased size of the leftmidbrain/thalamus lesionmeasuring 2.93×1.86 cm.D) Failure of standard of care treatment prompted treatmentwith BCNU (150
mg/m2 every 6 weeks). Control MRI (11/08/2017) after 6 cycles of BCNU shows initial regression of the lesion measuring 1.53 × 0.95 cm. E) Control MRI (02/20/2018)
following Imatinib (400mg daily) treatment shows regression of the lesionmeasuring 9.66×7.16mm. F)Control MRI (05/14/2018) following continued Imatinib (400mg
daily) treatment shows stable lesion measuring 9.62 × 7.25 mm. G) Control MRI (07/19/2018) following continued Imatinib (400 mg daily) treatment shows stable lesion
measuring 9.54 × 7.22 mm. H) Control MRI (11/21/2018) following continued Imatinib (400 mg daily) treatment shows stable lesion measuring 9.66 × 7.16 mm.
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